secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001384101-23-000140
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q2 revenue $90.3M (+24% YoY); GM Urological Cancers Tina Nova resigns
------------------------------------------------------------------------------

- Total revenue $90.3M (+24% YoY); testing revenue $81.7M (+37%); test volume 31,809 (+28%).
- Net loss $8.4M (-$0.12 EPS), improved 12% YoY; cash from ops $17M in Q2; cash $191M.
- Biopharma revenue $4.6M (-55% YoY); product revenue $4.0M (+29%).
- Tina Nova resigns as GM Urological Cancers (eff. Sept 3); advisor role $10k/month for 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410123000140/0001384101-23-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410123000140/vcyt-20230804.htm
  HTML page:      https://secwatch.observer/filing/0001384101-23-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer